|
Press Releases |
|
|
|
Thursday, June 29, 2023 |
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
Wednesday, September 16, 2020 |
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
Wednesday, May 20, 2020 |
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
Tuesday, March 17, 2020 |
|
NanoViricides公司冠状病毒药物开发更新 |
NanoViricides公司(美国纽约证券交易所交易代码 NNVC)(公司)是基于新型纳米药学平台(公司)开发高效抗病毒治疗方法的领先公司,目前正在为造成COVID-19的当前新型冠状病毒SARS-CoV-2进行药物开发,现提供其工作相关更新。 more info >> |
|
NanoViricides公司冠狀病毒藥物開發更新 |
NanoViricides公司(美國紐約證券交易所交易代碼NNVC)(公司)是基於新型納米藥學平台(公司)開發高效抗病毒治療方法的領先公司,目前正在為造成COVID-19的當前新型冠狀病毒SARS-CoV-2進行藥物開發,現提供其工作相關更新。 more info >> |
|
NanoViricides社、新型コロナウイルス治療薬開発に関する最新情報を発表 |
新たなナノ医療プラットフォームを基盤に非常に効果的な抗ウイルス療法の開発でリードするNanoViricides社(NYSE American: NNVC) (以下「当社」)は、COVID-19を引き起こす現在の新型コロナウイルス(SARS-CoV-2)の治療薬開発に向けた取り組みについて最新情報を提供しています。 more info >> |
|
Monday, March 16, 2020 |
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
健倍苗苗发布盈喜
May 5, 2024 11:00 HKT/SGT
|
|
|
健倍苗苗發佈盈喜
May 5, 2024 11:00 HKT/SGT
|
|
|
JBM Healthcare Issues Positive Profit Alert
May 5, 2024 11:00 HKT/SGT
|
|
|
Aemetis to Review First Quarter 2024 Financial Results on May 9, 2024
May 4, 2024 01:00 HKT/SGT
|
|
|
Peapack Private Hires Jerry Dominguez as Senior Managing Director
May 4, 2024 01:00 HKT/SGT
|
|
|
UVify Sets New Guinness World Record With 5,293 IFO Drones in Spectacular Aerial Display
May 4, 2024 00:00 HKT/SGT
|
|
|
2024 CAP Consumer Survey Shows Increase in Piracy on Social Media and Messaging Platforms in Asia Pacific
May 3, 2024 20:40 HKT/SGT
|
|
|
SDAI Limited: Positive Outcomes Since New Board took over in June 2023
May 3, 2024 20:00 HKT/SGT
|
|
|
Loop Industries and Ester Industries Ltd. Announce Joint Venture Agreement to Build an Infinite Loop(TM) Manufacturing Facility in India
May 3, 2024 20:00 HKT/SGT
|
|
|
Singapore's top general insurer debuts trading on Asia's leading digital exchange, AltaX
May 3, 2024 10:30 HKT/SGT
|
|
|
Nephros Schedules First Quarter 2024 Financial Results Conference Call
May 3, 2024 08:31 HKT/SGT
|
|
|
Nass Valley Gateway Ltd Announces It Will File Its 2023 EOY Audited Financials by June 28th, 2024, Within the Extension Granted by the BCSC
May 3, 2024 08:26 HKT/SGT
|
|
|
UPDATE: Kaplan Fox Files Class Action to Recover Losses for Investors Who Were Short The Barclays Bank PLC iPath Series B S&P 500 VIX Short-Term Futures ETN (CBOE: VXX) ("VXX")
May 3, 2024 08:05 HKT/SGT
|
|
|
长江电力公布2023年年度业绩 营收利润双增长
May 2, 2024 23:00 HKT/SGT
|
|
|
長江電力公佈2023年年度業績 營收利潤雙增長
May 2, 2024 22:54 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|